Cargando…
No effect of a single supratherapeutic dose of lersivirine, a next-generation NNRTI, on QTc interval in healthy subjects
Autores principales: | Vourvahis, M, Wong, R, Ndongo, NM, O'Gorman, M, Tawadrous, M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The International AIDS Society
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3113011/ http://dx.doi.org/10.1186/1758-2652-13-S4-P225 |
Ejemplares similares
-
Lersivirine: a new NNRTI active across HIV-1 subtypes with a unique resistance profile
por: Mori, J, et al.
Publicado: (2010) -
Lenalidomide at Therapeutic and Supratherapeutic Doses Does Not Prolong QTc Intervals in the Thorough QTc Study Conducted in Healthy Men
por: Chen, Nianhang, et al.
Publicado: (2013) -
Effect of Therapeutic and Supratherapeutic Doses of Vonoprazan on the QT/QTc Interval in a Phase I Randomized Study in Healthy Subjects
por: Astruc, B, et al.
Publicado: (2017) -
A single supratherapeutic dose of ridaforolimus does not prolong the QTc interval in patients with advanced cancer
por: Lush, Richard M., et al.
Publicado: (2012) -
Thorough QT/QTc Evaluation of the Cardiac Safety of Secnidazole at Therapeutic and Supratherapeutic Doses in Healthy Individuals
por: Darpo, Borje, et al.
Publicado: (2017)